Relief Therapeutics Holding (XSWX:RLF) LT-Debt-to-Total-Asset: 0.03 (As of Jun. 2025)

What is Relief Therapeutics Holding LT-Debt-to-Total-Asset?

Relief Therapeutics Holding XSWX:RLF +4.90% 20 LT-Debt-to-Total-Asset is 0.03 as of Jun. 2025. GuruFocus rates XSWX:RLF with a GF Score™ of 20/100 and a GF Value™ of CHF6.28. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Relief Therapeutics Holding's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.03.

Relief Therapeutics Holding's long-term debt to total assets ratio increased from Jun. 2024 (0.03) to Jun. 2025 (0.03). It may suggest that Relief Therapeutics Holding is progressively becoming more dependent on debt to grow their business.

Relief Therapeutics Holding (XSWX:RLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Relief Therapeutics Holding LT-Debt-to-Total-Asset Related Terms

Relief Therapeutics Holding LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Relief Therapeutics Holding's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding LT-Debt-to-Total-Asset Chart

Relief Therapeutics Holding Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.03

Relief Therapeutics Holding Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.03	0.03	0.03	0.03

20GF Score

Relief Therapeutics Holding SA XSWX:RLF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Relief Therapeutics Holding LT-Debt-to-Total-Asset Calculation

Relief Therapeutics Holding's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1.663	/	53.224
	=	0.03

Relief Therapeutics Holding's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )	/	Total Assets (Q: Jun. 2025 )
	=	1.531	/	47.987
	=	0.03

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.03 mean?

Relief Therapeutics Holding (XSWX:RLF) has a LT-Debt-to-Total-Asset of 0.03 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Relief Therapeutics Holding and its competitors.

Is Relief Therapeutics Holding's LT-Debt-to-Total-Asset too high?

Relief Therapeutics Holding's current LT-Debt-to-Total-Asset is 0.03. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.

How does Relief Therapeutics Holding's LT-Debt-to-Total-Asset compare to KTTA and OSRH?

Relief Therapeutics Holding's LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Relief Therapeutics Holding stock overvalued right now?

Relief Therapeutics Holding (XSWX:RLF) has a current LT-Debt-to-Total-Asset of 0.03. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current LT-Debt-to-Total-Asset is 0.03 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?

Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued. The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.

Key valuation signals for XSWX:RLF:

LT-Debt-to-Total-Asset: 0.03
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
GF Score™: 20/100 with 5 warning signs

No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relief Therapeutics Holding Business Description

Industry Healthcare Biotechnology

Comparable Companies KTTA OSRH LIMN LNAI LEXX PMN CASI ITRM TRAW VYNE VRTX REGN ASX:CSL XBRU:UCB XKRX:207940 XBRU:ARGX ALNY ONC INSM XKRX:068270

Address Avenue de Secheron 15, Geneva, CHE, 1202

Website https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

20GF Score

Get the complete analysis for XSWX:RLF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.00

Price

CHF6.28

GF Value

View XSWX:RLF Analysis

See LT-Debt-to-Total-Asset data for all stocks →